WebGEMOX与GELOX方案化疗序贯放疗一线治疗早期结外鼻型NK/T ... Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2: A meta-analysis [J]. Luo ... WebJul 6, 2024 · Another prospective study of early-stage ENKTL was carried out in our center with GELOX chemotherapy followed by radiotherapy . The baseline characteristics of the patients were roughly the same compared with our study. In both studies, most patients were under 60 years and male. Nearly one-third of all patients had B symptoms.
How we treat NK/T-cell lymphomas - Journal of Hematology
WebMay 10, 2024 · Additionally, GELOX (gemcitabine, oxaliplatin, and L-asparaginase) has been utilized with a 2-year OS and PFS over 80% [ 26 ]. P-GEMOX has been evaluated in a relapsed/refractory population that showed a CR and ORR of 52% and 81%, respectively, and a 3-year OS of 58% [ 45 ]. In contrast to limited stage disease, radiation therapy is … WebGELOX regimen, the dose intensity of gemcitabine and oxaliplatin was 667 mg/m2 per week and 43 mg/m2 per week, respectively; and it was 625 mg/m2 per week and 42.5 mg/m2 … nanshan group china
FOLFOX Cancer information Cancer Research UK
WebOct 10, 2024 · Patients with disseminated disease, such as those with leukemia and extensive skin involvement, are treated with chemotherapy alone (modified SMILE or P-GemOx) followed by an auto-SCT in CR1. Patients who experience relapse within 6 months are treated with a gemcitabine-based regimen. WebJun 7, 2024 · Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy is not an optimal treatment of ENKL. 4, 5 No standard treatment has been established based on the results of randomized controlled trials because of … WebCompared with other chemotherapeutic regimens, pegaspargase plus gemcitabine and oxaliplatin (PGEMOX)/L-asparaginase plus gemcitabine and oxaliplatin (GELOX) was associated with a significantly higher ORR (92.9 vs. 51.6 %, P = 0.009) and a significantly improved 5-year OS (78.6 vs. 23.9 %, P = 0.010) in patients with stage I-II disease. mehro consultants